Cancer - SC-4005: A Phase 1/2 Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051)

What is the goal of this study?

The goal of this study is to evaluate the objective response rate, number of patients with dose-limiting toxicities and number of patients with adverse events for pembrolizumab therapy.

Who can join the study?

This study may be a good fit for children and young adults who:

• Are between 6 months and 17 years old, and
• Have a diagnosis of melanoma, lymphoma, solid tumor, classical Hodgkin lymphoma, or microsatellite-instability-high solid tumor

What will happen if my child takes part in this study?

You can read more about this study on clinicaltrials.gov.

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.